A practical reference on ICP-MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-14 and is reviewed periodically as new material appears.
Analytical verification commonly relies on high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Spectroscopic methods such as UV-visible absorption and electron paramagnetic resonance can probe the metal centre itself, since the d9 configuration of copper(II) produces characteristic signals. Elemental analysis or plasma-based techniques quantify copper content. Because each method reports a different aspect of the same sample, purity figures are most meaningful when the technique and its detection wavelength are stated alongside the value.
Stability of the complex in solution depends on pH, temperature, and the presence of competing ligands. It is generally described as more resistant to breakdown than the metal-free chain, since coordination reduces susceptibility to enzymatic attack. Oxidation and hydrolysis can nevertheless proceed over time in aqueous media. Storage guidance in laboratory settings commonly involves refrigeration, protection from light, and avoidance of strongly alkaline conditions. Published data on long-term behaviour vary considerably and depend on the specific matrix.
Handling practices for the solid material emphasise low temperature and dryness. The lyophilised or powdered form is typically kept at refrigerator or freezer temperatures together with a desiccant. Working solutions are often prepared fresh, because repeated freeze-thaw cycles and extended storage may alter the complex. Glass or inert plastic containers are preferred over materials that could leach metal ions into the preparation. Such practices follow general peptide conventions rather than substance-specific regulations.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, frequently paired with mass spectrometry to confirm the molecular ion. Copper content is measured separately, typically by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the chromatographic signal reports the peptide rather than the metal. Ultraviolet-visible spectroscopy provides a fast check on complex formation, since copper(II) peptide complexes absorb in the visible region. Elemental analysis and amino acid analysis are used less often but remain useful for reference standards. A gap between reported peptide purity and measured copper content is a recurring source of confusion.
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
| Property | Value | Notes |
|---|---|---|
| Appearance | Blue crystalline solid | Colour arises from copper(II) d-d transitions |
| Water solubility | Readily soluble | Extent varies with pH and counterion |
| Typical storage | Minus 20 degrees Celsius, desiccated | Protect from light and moisture |
| Purity method | Reverse-phase HPLC, UV detection | Wavelength typically 214 or 220 nanometres |
| Identity method | Mass spectrometry | Confirms peptide mass and copper content |
Quality control for GHK-Cu relies on documentation and independent testing rather than a single accepted standard. A certificate of analysis may report peptide purity, copper content, residual solvents, water content, and microbial limits, but the underlying methods and acceptance criteria vary by supplier. Verification can include mass confirmation, amino acid analysis, and comparison with a reference standard when one is available. Open questions include how different copper-binding modes or peptide isomers affect measured activity and whether conventional purity assays capture those differences. Buyers of research-grade material typically need to request raw data rather than rely solely on a summary certificate.
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
Analytical verification typically combines reversed-phase high-performance liquid chromatography with ultraviolet-visible detection. The copper complex absorbs visible light near 600–630 nm, giving a characteristic blue signal. Mass spectrometry confirms molecular mass and can detect free peptide or mismatched copper stoichiometry. Copper content is often measured independently by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. Purity, counterion identity, and residual solvents are additional quality-control parameters that methods may address.
Solid GHK-Cu is generally stored as a dry powder under frozen conditions to limit degradation. The peptide bond can hydrolyze, and the copper center can be displaced by strong chelators such as EDTA. Aqueous solutions are less stable than the solid and may lose color or form precipitates over time. Temperature, pH, and oxygen exposure are the main variables that affect shelf life. Neutral to slightly acidic conditions tend to preserve the complex better than strongly alkaline media.
Identity and purity are normally checked by reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry. The peptide absorbs in the ultraviolet region, and the copper complex also shows a broad visible absorption band that can be followed spectroscopically. Copper content is measured separately, for example by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not confirm how much metal is bound. Purity figures therefore need a stated basis: peptide peak area, copper content, or both.
Aqueous GHK-Cu solutions are less stable than the dry powder. Light, dissolved oxygen and elevated temperature all accelerate loss of the intact complex, and the main observable changes are fading of the blue colour and the appearance of peptide fragments. Acidic conditions protonate the histidine imidazole and weaken copper binding, while strongly alkaline conditions promote hydrolysis of the peptide backbone. Because several degradation routes operate at once, a single shelf-life figure does not describe all storage conditions.
Solid material is typically kept as a lyophilised powder in a sealed, light-protected container at minus 20 degrees Celsius, with desiccant where humidity is high. Working solutions are often prepared fresh, aliquoted and frozen to avoid repeated freeze-thaw cycles. Glassware and buffers are checked for trace metal contamination, since other transition metals can displace copper. Records of lot number, reconstitution date and storage temperature help trace unexpected colour changes. Blue colour itself is not a reliable purity test, because partly degraded solutions can remain visibly coloured.
The molecular weight and charge of GHK-Cu depend on the pH and the number of coordinated ligands. At neutral pH, the peptide typically binds one copper ion, but ternary complexes with other biomolecules can form. Spectroscopic methods such as electron paramagnetic resonance and circular dichroism are used to study the coordination environment. Reports on the exact geometry vary because the complex is dynamic in solution. Researchers often use synthetic GHK-Cu rather than extracted material to control stoichiometry and purity.
GHK-Cu is a coordination complex formed from the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, the terminal amino group, and the deprotonated amide nitrogen. This arrangement creates a square-planar or distorted geometry around the metal center, depending on pH and the presence of competing ligands. The complex occurs naturally in human plasma, saliva, and urine at low concentrations, and its sequence is conserved across many vertebrate species.
Discovery of GHK is generally attributed to work in the 1970s that isolated a plasma factor influencing liver cell behavior. Subsequent studies identified the copper-binding tripeptide and its ability to chelate copper with high affinity. Early reports linked the complex to wound healing and tissue remodeling in animal models. The free peptide and the copper-bound form have different properties, so the two are distinguished in the literature. Whether endogenous GHK-Cu serves a single primary physiological role remains an open question.
Development chamber preparation: The development solvent or solvent mixture is placed into a transparent container (separation/development chamber) to a depth of less than 1 centimetre. A strip of filter paper (aka "wick") is also placed along the container wall. This filter paper should touch the solvent and almost reach the top of the container. The container is covered with a lid and the solvent vapors are allowed to saturate the atmosphere of the container. Failure to do so results in poor separation and non-reproducible results. Development: The TLC plate is placed in the container such that the sample spot(s) are not submerged into the mobile phase. The container is covered to prevent solvent evaporation. The solvent migrates up the plate by capillary action, meets the sample mixture, and carries it up the plate (elutes the sample). The plate is removed from the container before the solvent reaches the top of the plate; otherwise, the results will be misleading. The solvent front, the highest mark the solvent has travelled along the plate, is marked. Visualization: The solvent evaporates from the plate. Visualization methods include UV light, staining, and many more.
=== The Taghi organisation === Ridouan Taghi is a former Dutch-Moroccan drug trafficker and crime boss. He was specialised in forming criminal groups and coalitions that operated as international cocaine cartels. He is suspected of being behind the orchestration of several assassinations, attacks, and kidnappings in connection to the Mocro-War. Documents produced by the Drug Enforcement Administration (DEA) of the United States, and sent to the Dutch police, exposed what appeared to be a super drug cartel headed by Ridouan Taghi, alongside Raffaele Imperiale (Camorra's drugs and arms dealer), Daniel Kinahan (Irish reputed gang boss) and Edin Gačanin (Bosnian drug trafficker). The DEA estimated that around a third of all cocaine trafficking in Europe was done through his organisation, with a virtually monopoly on Peruvian cocaine. After the decryption of the telecommunication servers of Ennetcom by the Dutch and Canadian authorities, it also exposed a very close and personal friendship between Ridouan Taghi, and Chilean cartel boss Rico "El Rico" Eduardo Riquelme Vega, who was arrested in Santiago, Chile in 2017. Following the arrest of Benaouf A. in 2013, and the assassinations of two rival drug lords, Gwenette Martha and Samir Bouyakhrichan in 2014, Taghi was able to establish himself as one of the most powerful drug traffickers in Europe. The Dutch government also considered him to be "one of the most dangerous drug traffickers in Europe". Ridouan Taghi was able to keep a very low profile and run his operation unknowingly for many years.
== History and Development == Tagging technology and instrument development occurred at the University of Toronto and DVS Sciences, Inc. CyTOF (cytometry by time of flight) was initially commercialized by DVS Sciences in 2009. In 2014, Fluidigm acquired DVS Sciences to become a reference company in single cell technology. The technology evolved through models like CyTOF, CyTOF2, Helios (CyTOF3) and CyTOF XT, with the latter announced in 2021. In 2022 Fluidigm received a capitol infusion and changed its name to Standard BioTools. In 2023, Standard BioTools introduced the Hyperion XTi Imaging System, advancing Imaging Mass Cytometry (IMC) with capabilities such as whole slide imaging, automated sample processing, and dual imaging/flow cytometry modes. In 2024, the company expanded its high-throughput imaging options with two additional rapid modes and an automated slide loader that can be installed directly on the Hyperion XTi for automatic loading and acquisition of up to 40 slides. Additionally, a 2024 collaboration with Navignostics was announced to develop clinical research applications using the Hyperion XTi system . In 2025, Standard BioTools announced the CyTOF XT Pro System, streamlining workflow with up to 4x faster throughput and software with 21 CFR Part 11 compliance enabling features.
Eteplirsen (brand name Exondys 51) is a medication to treat, but not cure, some types of Duchenne muscular dystrophy (DMD), caused by a specific mutation. Eteplirsen only targets specific mutations and can be used to treat about 14% of DMD cases. Eteplirsen is a form of antisense therapy. Eteplirsen was developed by Steve Wilton, Sue Fletcher and colleagues at the University of Western Australia and commercialized by Sarepta Therapeutics. After a controversial debate surrounding the drug's efficacy, during which two FDA review panel members resigned in protest, eteplirsen received accelerated approval from the US Food and Drug administration in late 2016. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) refused to authorize the use of eteplirsen.
Sources: en.wikipedia.org
Droplet-based microfluidics manipulate discrete volumes of fluids in immiscible phases with low Reynolds number (<< 2300) and laminar flow regimes. An early example for using droplet-based microfluidics was a flow-through chip reactor for miniaturized PCR. Interest in droplet-based microfluidics systems has been growing substantially in past decades. Microdroplets offer the feasibility of handling miniature volumes (μL to fL) of fluids conveniently, provide better mixing, encapsulation, sorting, sensing and are suitable for high throughput experiments. Two immiscible phases used for the droplet based systems are referred to as the continuous phase (medium in which droplets flow) and dispersed phase (the droplet phase), resulting in either water-in-oil (W/O) or oil-in-water (O/W) emulsion droplets.
Glyceroneogenesis is a metabolic pathway which synthesizes glycerol 3-phosphate (used to form triglycerides) from precursors other than glucose. Usually, glycerol 3-phosphate is generated from glucose by glycolysis, in the liquid of the cell's cytoplasm (the cytosol). Glyceroneogenesis is used when the concentrations of glucose in the cytosol are low, and typically uses pyruvate as the precursor, but can also use alanine, glutamine, or any substances from the TCA cycle. The main regulator enzyme for this pathway is an enzyme called phosphoenolpyruvate carboxykinase (PEPC-K), which catalyzes the decarboxylation of oxaloacetate to phosphoenolpyruvate. Glyceroneogenesis is observed mainly in adipose tissue, and in the liver. A significant biochemical pathway regulates cytosolic lipid levels. Intense suppression of glyceroneogenesis may lead to metabolic disorders such as type 2 diabetes.
In February 2024, the Palestinian Red Crescent reported that a paramedic unit had gone missing attempting to rescue six-year-old Hind Rajab. In released audio of the emergency call, Rajab is heard telling the paramedics, "I'm so scared. Please come," with gunfire in the background immediately after the family's car had been hit by an Israeli tank. On 3 February, the media director of the Palestinian Red Crescent stated only Israeli forces knew what had happened to Hind. On 5 February, one week after the attack, Rajab's mother stated, "I have been appealing to the whole world, but no one moved a finger." Her grandfather stated, "We want to know her fate, whatever it was." On 8 February, ten days after Rajab went missing, the Palestinian Red Crescent stated, "We want answers, we want the truth, we need the painful silence to end." On 10 February 2024, Rajab was found dead along with the bodies of the two paramedics.
The musculoskeletal system consists of the human skeleton (which includes bones, ligaments, tendons, joints and cartilage) and attached muscles. It gives the body basic structure and the ability for movement. In addition to their structural role, the larger bones in the body contain bone marrow, the site of production of blood cells. Also, all bones are major storage sites for calcium and phosphate. This system can be split up into the muscular system and the skeletal system.
=== Available forms === Buserelin is available in the form of a 1 mg/mL solution for use as a nasal spray or subcutaneous injection once every 8 hours (three times per day) and as 6.3 mg and 9.45 mg implants for subcutaneous injection once every two and three months, respectively.
Sources: en.wikipedia.org
These cyclic dipeptides incorporate both donor and acceptor groups for hydrogen bonding. They are conformationally constrained nearly planar scaffolds. Diversity can be introduced at up to six positions and stereochemistry controlled at up to four positions. They are stable to proteolysis. These characteristics underpin theis biologically activity and utility in medicinal chemistry. As a consequence of their predominant biosynthetic origin from L-α-amino acids most naturally occurring 2,5-DKPs are cis configured as the cyclo(L-Xaa-L-Yaa) isomers. 2,5-DKPs epimerize under basic, acidic and thermal conditions. The composition of the cis and trans isomers in the equilibrium state varies widely depending on the bulk of the side chains, if a ring (e.g. proline) is present, or if the nitrogen atoms are alkylated . Although epimerization was historically an issue in the synthesis of 2,5-DKPs, several mild methods have been developed recently that avoid epimerization.
Myasthenia gravis Acute intoxication with alcohol, narcotics, or other psychoactive substances Ataxia Severe hypoventilation Acute narrow-angle glaucoma Severe liver deficiencies (hepatitis and liver cirrhosis decrease elimination by a factor of 2) Severe sleep apnea Hypersensitivity or allergy to any drug in the benzodiazepine class Chlordiazepoxide is generally considered an inappropriate benzodiazepine for the elderly due to its long elimination half-life and the risks of accumulation. Benzodiazepines require special precaution if used in the elderly, pregnancy, children, alcohol- or drug-dependent individuals and individuals with comorbid psychiatric disorders.
Handheld electronics mostly use lithium polymer batteries (with a polymer gel as an electrolyte), a lithium cobalt oxide (LiCoO2) cathode material, and a graphite anode, which together offer high energy density. Lithium iron phosphate (LiFePO4), lithium manganese oxide (LiMn2O4 spinel, or Li2MnO3-based lithium-rich layered materials, LMR-NMC), and lithium nickel manganese cobalt oxide (LiNiMnCoO2 or NMC) may offer longer life and a higher discharge rate. NMC and its derivatives are widely used in the electrification of transport, one of the main technologies (combined with renewable energy) for reducing greenhouse gas emissions from vehicles. Lithium nickel cobalt aluminum oxide (NCA) is another high-energy lithium-ion chemistry commonly used in electric vehicle batteries.
=== Objectives === Recovery point objective (RPO): The point in time that the restarted infrastructure will reflect, expressed as "the maximum targeted period in which data (transactions) might be lost from an IT service due to a major incident". Essentially, this is the roll-back that will be experienced as a result of the recovery. The most desirable RPO would be the point just prior to the data loss event. Making a more recent recovery point achievable requires increasing the frequency of synchronization between the source data and the backup repository. Recovery time objective (RTO): The amount of time elapsed between disaster and restoration of business functions. Data security: In addition to preserving access to data for its owners, data must be restricted from unauthorized access. Backups must be performed in a manner that does not compromise the original owner's undertaking. This can be achieved with data encryption and proper media handling policies. Data retention period: Regulations and policy can lead to situations where backups are expected to be retained for a particular period, but not any further. Retaining backups after this period can lead to unwanted liability and sub-optimal use of storage media. Checksum or hash function validation: Applications that back up to tape archive files need this option to verify that the data was accurately copied.
=== Genome === Sequencing of the laboratory mouse genome was completed in late 2002 using the C57BL/6 strain. This was only the second mammalian genome to be sequenced after humans. The haploid genome is about three billion base pairs long (3,000 Mb distributed over 19 autosomal chromosomes plus 1 respectively 2 sex chromosomes), therefore equal to the size of the human genome. Estimating the number of genes contained in the mouse genome is difficult, in part because the definition of a gene is still being debated and extended. The current count of primary coding genes in the laboratory mouse is 23,139. compared to an estimated 20,774 in humans.
Sources: en.wikipedia.org
Reverse-phase high-performance liquid chromatography with ultraviolet detection is the most common approach. Purity is expressed as a share of total peak area at a specified wavelength. Mass spectrometry is then used to confirm molecular identity.
Solid material is often held at refrigerator or freezer temperatures, typically between minus 20 and 4 degrees Celsius. Desiccation limits moisture uptake. Solution stability is generally shorter and varies with pH and buffer composition.
Electron paramagnetic resonance is suited to copper(II) because of its unpaired electron. UV-visible spectroscopy reveals ligand-to-metal charge transfer bands. Both methods report on coordination rather than on peptide purity.
The solid is typically held cold and dry, and solutions are kept for shorter periods because hydrolysis proceeds in water. Repeated freeze-thaw cycles are usually avoided, since they can degrade both the peptide and the complex. Container material and headspace also affect how long a sample remains unchanged.